I think 1 thing mentioned in the protocol changes, points to Cytodyn deciding to go further solo than it is yet realized.
One of the significant posts, briefly referencing Dr. J mentioned dosing amounts/duration, needs to established. (Will post it for credit when I find it again).
But, what was not mentioned, is Dr. J said --- a 3rd-party would fund Dosing/Duration in Phase 3, as it is needed for an FDA approval.
Cytodyn just adjusted to qualify Dose/Duration. The mCRC data seen to date, for ME, has made Cytodyn decide to seriously up our leverage into any partnership, & why we now see Dosing/Duration will be included in our $17.5m funding us "into 2027".
Weeks ago I wrongly said Cytodyn could buy a Voucher. But said -- either buy ...or recieve a Voucher, from the FDA.
mCRC &/or Glio results --- could equal that Paradim Shift & very possibly alot quicker than we think via combining a Voucher & addtl FDA programs mentioned.
Now add Dosing & Duration on our own, to this list from days ago, & Cytodyn's advantages in any "discussions", is simply staggering.
Leronlimab is truly the Plug-n-Play of mankind:
my69z
Mar 29, 2026 12:42 PM
$CYDY This company is not structured for buy-out
Everything started will need to be Fidicuary Duty addressed by Dr. J & the BOD ---- or serious legalities start
Makes no sense that they would be willy nilly digging a whole / wholes....for themselves to just fall into. With in addition to hundreds, if not close to 1k indications with tumors & Rare Diseases.....
No need for :
30k employees
High insurance
Crappy margins
Owning trial sites
High lobbying fee
Huge sales teams
Huge marketing teams
Multiple types of mfgr'ing
Multiple types of distribution
Top heavy legal departments
Being a low-level company, owning the only non-toxic multi-MOA sequence drug for humanity, gives you the "easiest" drug-to-market path, could possibly envision.
Cytodyn clearly intends to get Leronlimab to market.
And I love it ......
One of the significant posts, briefly referencing Dr. J mentioned dosing amounts/duration, needs to established. (Will post it for credit when I find it again).
But, what was not mentioned, is Dr. J said --- a 3rd-party would fund Dosing/Duration in Phase 3, as it is needed for an FDA approval.
Cytodyn just adjusted to qualify Dose/Duration. The mCRC data seen to date, for ME, has made Cytodyn decide to seriously up our leverage into any partnership, & why we now see Dosing/Duration will be included in our $17.5m funding us "into 2027".
Weeks ago I wrongly said Cytodyn could buy a Voucher. But said -- either buy ...or recieve a Voucher, from the FDA.
mCRC &/or Glio results --- could equal that Paradim Shift & very possibly alot quicker than we think via combining a Voucher & addtl FDA programs mentioned.
Now add Dosing & Duration on our own, to this list from days ago, & Cytodyn's advantages in any "discussions", is simply staggering.
Leronlimab is truly the Plug-n-Play of mankind:
my69z
Mar 29, 2026 12:42 PM
$CYDY This company is not structured for buy-out
Everything started will need to be Fidicuary Duty addressed by Dr. J & the BOD ---- or serious legalities start
Makes no sense that they would be willy nilly digging a whole / wholes....for themselves to just fall into. With in addition to hundreds, if not close to 1k indications with tumors & Rare Diseases.....
No need for :
30k employees
High insurance
Crappy margins
Owning trial sites
High lobbying fee
Huge sales teams
Huge marketing teams
Multiple types of mfgr'ing
Multiple types of distribution
Top heavy legal departments
Being a low-level company, owning the only non-toxic multi-MOA sequence drug for humanity, gives you the "easiest" drug-to-market path, could possibly envision.
Cytodyn clearly intends to get Leronlimab to market.
And I love it ......
4
